3902. Reduced Replication Efficacy of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in "Mini-gut" Organoids.
作者: Kei Miyakawa.;Masakazu Machida.;Tomoyuki Kawasaki.;Mayuko Nishi.;Hidenori Akutsu.;Akihide Ryo.
来源: Gastroenterology. 2022年163卷2期514-516页 3909. A Chromosomal Duplication Encompassing Interleukin-33 Causes a Novel Hyper IgE Phenotype Characterized by Eosinophilic Esophagitis and Generalized Autoimmunity.
作者: Ashish K Marwaha.;Ronald Laxer.;Minggao Liang.;Aleixo M Muise.;Thomas Eiwegger.; .
来源: Gastroenterology. 2022年163卷2期510-513.e3页 3917. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
作者: Yi Zhang.;Hongwei Xu.;Guofei Cui.;Binyong Liang.;Xiangzheng Chen.;Sungjin Ko.;Silvia Affo.;Xinhua Song.;Yi Liao.;Jianguo Feng.;Pan Wang.;Haichuan Wang.;Meng Xu.;Jingxiao Wang.;Giovanni M Pes.;Silvia Ribback.;Yong Zeng.;Aatur Singhi.;Robert F Schwabe.;Satdarshan P Monga.;Matthias Evert.;Liling Tang.;Diego F Calvisi.;Xin Chen.
来源: Gastroenterology. 2022年163卷2期481-494页
YES-associated protein (YAP) aberrant activation is implicated in intrahepatic cholangiocarcinoma (iCCA). Transcriptional enhanced associate domain (TEAD)-mediated transcriptional regulation is the primary signaling event downstream of YAP. The role of Wnt/β-Catenin signaling in cholangiocarcinogenesis remains undetermined. Here, we investigated the possible molecular interplay between YAP and β-Catenin cascades in iCCA.
3918. Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer.
作者: C Richard Boland.;Gregory E Idos.;Carol Durno.;Francis M Giardiello.;Joseph C Anderson.;Carol A Burke.;Jason A Dominitz.;Seth Gross.;Samir Gupta.;Brian C Jacobson.;Swati G Patel.;Aasma Shaukat.;Sapna Syngal.;Douglas J Robertson.
来源: Gastroenterology. 2022年162卷7期2063-2085页
The gastrointestinal hamartomatous polyposis syndromes are rare, autosomal dominant disorders associated with an increased risk of benign and malignant intestinal and extraintestinal tumors. They include Peutz-Jeghers syndrome, juvenile polyposis syndrome, the PTEN hamartoma tumor syndrome (including Cowden's syndrome and Bannayan-Riley-Ruvalcaba syndrome), and hereditary mixed polyposis syndrome. Diagnoses are based on clinical criteria and, in some cases, confirmed by demonstrating the presence of a germline pathogenic variant. The best understood hamartomatous polyposis syndrome is Peutz-Jeghers syndrome, caused by germline pathogenic variants in the STK11 gene. The management is focused on prevention of bleeding and mechanical obstruction of the small bowel by polyps and surveillance of organs at increased risk for cancer. Juvenile polyposis syndrome is caused by a germline pathogenic variant in either the SMAD4 or BMPR1A genes, with differing clinical courses. Patients with SMAD4 pathogenic variants may have massive gastric polyposis, which can result in gastrointestinal bleeding and/or protein-losing gastropathy. Patients with SMAD4 mutations usually have the simultaneous occurrence of hereditary hemorrhagic telangiectasia (juvenile polyposis syndrome-hereditary hemorrhagic telangiectasia overlap syndrome) that can result in epistaxis, gastrointestinal bleeding from mucocutaneous telangiectasias, and arteriovenous malformations. Germline pathogenic variants in the PTEN gene cause overlapping clinical phenotypes (known as the PTEN hamartoma tumor syndromes), including Cowden's syndrome and related disorders that are associated with an increased risk of gastrointestinal and colonic polyposis, colon cancer, and other extraintestinal manifestations and cancers. Due to the relative rarity of the hamartomatous polyposis syndromes, recommendations for management are based on few studies. This U.S Multi-Society Task Force on Colorectal Cancer consensus statement summarizes the clinical features, assesses the current literature, and provides guidance for diagnosis, assessment, and management of patients with the hamartomatous polyposis syndromes, with a focus on endoscopic management.
3919. Prediction Models for Celiac Disease Development in Children From High-Risk Families: Data From the PreventCD Cohort.
作者: Caroline R Meijer.;Renata Auricchio.;Hein Putter.;Gemma Castillejo.;Paula Crespo.;Judit Gyimesi.;Corina Hartman.;Sanja Kolacek.;Sibylle Koletzko.;Ilma Korponay-Szabo.;Eva Martinez Ojinaga.;Isabel Polanco.;Carmen Ribes-Koninckx.;Raanan Shamir.;Hania Szajewska.;Riccardo Troncone.;Vincenzo Villanacci.;Katharina Werkstetter.;M Luisa Mearin.
来源: Gastroenterology. 2022年163卷2期426-436页
Screening for celiac disease (CD) is recommended in children with affected first-degree relatives (FDR). However, the frequency of screening and at what age remain unknown. The aims of this study were to detect variables influencing the risk of CD development and develop and validate clinical prediction models to provide individualized screening advice.
|